Current clinical trials department of neurological surgery, university of wisconsin pain after endometrial biopsy

A research project collecting pilot data to evaluate surgical approaches and outcomes in surgery for patients with Chiari type I malformation and Syringomyelia. The study will collect data on the characteristics of subjects who ultimately undergo surgical intervention. Dr. Iskandar and the University of Wisconsin School of Medicine and Public Health will be the coordinating center collecting and compiling data from 12 clinical sites across the United States.

The purpose of this study is to create the Park Reeves Syringomyelia Registry, a multi-institutional, online, comprehensive database to collect and store prospective and retrospective data regarding Chiari I Malformations and Syringomyelia. Results from this study will help better understand the pathogenesis of Syringomyelia and how best to treat it as well as answer long-standing questions regarding the optimal surgical techniques for Chiari Malformation.


The University of Wisconsin School of Medicine and Public Health and the American Family Children’s Hospital are one of more than 30 clinical sites across the United States participating in this study.

Chiari type I malformation and Syringomyelia is treated with neurosurgical decompressin of the cranioverebral junction with either of two technical variations: posterior fossa decompression with duraplasty (PFDD) or posterior fossa decompression without duraplasty (PFD) The Hypothesis of this study is that PFD will be associated with fewer surgical complications and less harm to patients that PFDD. The University of Wisconsin School of Medicine and Public Health and the American Family Children’s Hospital are one of 47 clinical sites across the United States participating in this study.

A research project looking at the differences in the plaque in people with symptomatic and asymptomatic carotid stenosis (narrowing of the carotid arteries). The study uses various techniques to look at the differences in people who have carotid stenosis and the causes and consequences of carotid stroke.

This study is a Phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of Intracerebral Hemorrhage (ICH). The purpose is to determine the efficacy of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove ICH improves functional outcome. The University of Wisconsin School of Medicine and Public Health is one of over 70 locations worldwide participating in this trial.

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in the event-free survival at 90 days in those treated with clopidogrel (600 mg loading dose then 75 mg/day) compared to placebo when subjects are randomized within 12 hours of time last known free of new ischemic symptoms. A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale [NIHSS] score less than or equal to 3).

The main purpose for this pilot registry is research and quality improvement for spine care. The NASS Spine Registry Pilot aims to test registry processes ultimately aimed at collecting data to enhance understanding of spine care treatments and their resulting patient outcomes, as well as examine the natural history of spine disorders. 13 site across the U.S are participating in this Pilot study.

This is an international, multi-center, prospective, double-blinded, randomized, placebo-controlled Phase II/III clinical trial to evaluate if Riluzole at a dose of 100 mg BID for the first 24 hours followed by 50 mg BID for 13 days is superior to placebo in subjects with acute traumatic Spinal Cord Injury (SCI).

The purpose of the study is to determine the optimal surgical approach (ventral vs dorsal) for patients with multi-level cervical spondylotic myelopathy (CSM). There are no established guidelines for the management of patients with CSM, which represents the most common cause of spinal cord injury and dysfunction in the US and in the world. The University of Wisconsin School of Medicine and Public Health is one of over 15 locations in the U.S. participating in this trial.

This study is a prospective, randomized, multi-center, Phase III, adaptive design, population enrichment, blinded endpoint, controlled trial. The purpose is to evaluate if endovascular treatment leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-16 hours after stroke onset. The University of Wisconsin School of Medicine and Public Health is one of 45 locations in the U.S. participating in this trial.